3.12
+0.04(+1.30%)
Currency In CAD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
82
First IPO Date
January 09, 2014
| Name | Title | Pay | Year Born |
| Mr. Kenneth d'Entremont | Chief Executive Officer & Director | 1.45M | N/A |
| Mr. Brian Peters | Vice President of Sales & Marketing - United States | 396,695 | N/A |
| Mr. Richard Labelle | Chief Operating Officer | 482,291 | N/A |
| Mr. Ian C. Wildgoose Brown | General Counsel & Corporate Secretary | 592,667 | N/A |
| Mr. Bill Poncy | Senior Vice President of Commercial Operations - United States | 613,601 | N/A |
| Ms. Tina Byers CFA | Executive of Investor Relations | 0 | N/A |
| Mr. Brendon Buschman | Chief Financial Officer | 0 | N/A |
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.